| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/20/2003 | WO2002076437A3 Methods for treating neurodegenerative diseases including alzheimer's |
| 02/20/2003 | WO2002076398A3 Improved forms of pharmaceutically active agents and method for manufacture thereof |
| 02/20/2003 | WO2002074922A3 Compositions and methods for modulating an immune response |
| 02/20/2003 | WO2002074742A3 Cdk-inhibitory indirubin derivatives having an increased solubility |
| 02/20/2003 | WO2002074246A3 Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds |
| 02/20/2003 | WO2002074228A3 Pharmaceutical composition for the treatment of diabetes comprising a 5-phenoxyalkal-2,4-thiazolidinedione derivative and a compound that stimulates insulin secretion |
| 02/20/2003 | WO2002072585A3 Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics |
| 02/20/2003 | WO2002072003A3 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour |
| 02/20/2003 | WO2002070525A3 Nitrogen-based camptothecin derivatives |
| 02/20/2003 | WO2002068548A9 Use of erss-selective ligands for regulating fertility and compounds useful therefore |
| 02/20/2003 | WO2002068399B1 Aryl carbamate derivatives, preparation and use thereof |
| 02/20/2003 | WO2002068387A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/20/2003 | WO2002067998A3 Devices and methods for the treatment of cancer |
| 02/20/2003 | WO2002067878A3 Use of mil thistle extract in skin care compositions |
| 02/20/2003 | WO2002066029A3 Antiprotozoal methods, compositions and feedstuffs |
| 02/20/2003 | WO2002065979A3 (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes |
| 02/20/2003 | WO2002064126A3 Method of treating of demyelinating diseases or conditions |
| 02/20/2003 | WO2002064109A3 Mucoadhesive pharmaceutical formulations |
| 02/20/2003 | WO2002064026A3 Treating pulmonary disorders with gaseous agent causing repletion of gsno |
| 02/20/2003 | WO2002060406A3 Veterinary dermatologic composition |
| 02/20/2003 | WO2002054933A3 Method for photodynamic therapy and applicator for carrying out said therapy |
| 02/20/2003 | WO2002053122B1 Skin care product containing retinoids and phytoestrogens in a dual compartment package |
| 02/20/2003 | WO2002053090A3 Medicinal association of a biguanine (metformin) and arginine |
| 02/20/2003 | WO2002051427A8 Improved and stable extract from hypericum perforatum l., method for the production thereof and its use as a topical medicament |
| 02/20/2003 | WO2002050058A8 Crystal forms of 6-[(4-chloro-phenyl) -hydroxy-(-3-methyl- 3h-imidaol-4-yl) -methyl] -4-(3-ethynyl-phenyl) -1-methyl-1h- quinolin-2-one, 2,3- dihydroxybutanedioate salts and method of production |
| 02/20/2003 | WO2002049993A3 High affinity small molecule c5a receptor modulators |
| 02/20/2003 | WO2002047730A8 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins |
| 02/20/2003 | WO2002043731A3 Treatments for neurogenetic disorders, impulse control disorders, and wound healing |
| 02/20/2003 | WO2002042295A3 Peptides as met-ap2 inhibitors |
| 02/20/2003 | WO2002039999A3 Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition |
| 02/20/2003 | WO2002039956A3 Black tea extract for prevention of disease |
| 02/20/2003 | WO2002032974A3 Polymer and its use for the treatment and/or prevention of hyperphosphoremia |
| 02/20/2003 | WO2002032842A9 Compounds with high monoamine transporter affinity |
| 02/20/2003 | WO2002030882A9 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 02/20/2003 | WO2002030860A9 Ketone compounds and compositions for cholesterol management and related uses |
| 02/20/2003 | WO2002028391A9 Blocking inflammation by inhibiting sialylation |
| 02/20/2003 | WO2002028180B1 Antimicrobial compositions formulated for use in cold temperature conditions and methods of use thereof |
| 02/20/2003 | WO2002026950A3 Transferases |
| 02/20/2003 | WO2002026236A9 Tumor cell killing by cell cycle checkpoint abrogation combined with inhibition of the 'classical' mitogen activated protein (map) kinase pathway |
| 02/20/2003 | WO2002026224A9 Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation |
| 02/20/2003 | WO2002026193A9 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas |
| 02/20/2003 | WO2002024635A3 Aminoalcohol derivatives |
| 02/20/2003 | WO2002024158A8 Pulmonary delivery in treating disorders of the central nervous system |
| 02/20/2003 | WO2002022621B1 INTERPHENYLENE 7-OXABICYCLIC[2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2a ANTAGONISTS |
| 02/20/2003 | WO2002019842A2 Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof |
| 02/20/2003 | WO2002015940A3 Solution of an oxazolidinone antibiotic drug |
| 02/20/2003 | WO2001093850B1 Methods and compositions using sulodexide for the treatment of diabetic nephropathy |
| 02/20/2003 | WO2001091741B1 Compositions containing hexitol and an antiproliferative agent |
| 02/20/2003 | WO2001064949A9 Diagnostics and therapeutics for glaucoma |
| 02/20/2003 | WO2001056547B1 Preparation of aqueous clear solution dosage forms with bile acids |
| 02/20/2003 | WO2001022952A3 Use of tace inhibitors |
| 02/20/2003 | US20030037350 Nucleotide sequences coding polypeptides for use in the treatment and diagnosis of cancer and nervous system disorders |
| 02/20/2003 | US20030036653 For prophylaxis and therapy of diseases associated with herpes viruses including human cytomegalovirus, herpes simplex viruses, Epstein-Barr virus, varicella-zoster virus, human herpesviruses- 6 and -7, and Kaposi herpesvirus |
| 02/20/2003 | US20030036652 Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines |
| 02/20/2003 | US20030036649 2' modified oligonucleotides |
| 02/20/2003 | US20030036645 Breast cancer resistance protein (BCRP) and the DNA which encode it |
| 02/20/2003 | US20030036642 Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
| 02/20/2003 | US20030036568 Permeation enhancers |
| 02/20/2003 | US20030036567 Propylene glycol as an agent to stimuate thrombopoiesis |
| 02/20/2003 | US20030036566 Administering 4-chloro-1-(p-(2-hydroxyethoxy)phenyl)-1,2-diphenyl-1-butene or a geometric isomer, a stereoisomer, a salt, an ester thereof or a metabolite thereof |
| 02/20/2003 | US20030036565 Increasing the chemoprotective amount of at least one Phase II enzyme, particulary a phase II enzyme, in a mammal by administering an extract comprising a betalain. |
| 02/20/2003 | US20030036564 Controlling the spread of Lyme disease by orally administering to infected rodents in the wild chloramphenicol, thiamphenicol, florfenicol, or a salt or derivative thereof. |
| 02/20/2003 | US20030036563 Carboxyvinylpolymer neutralized as a gel-forming agent or a polyacrylamide-isoparaffin and ethanol, isopropanol or diethylene glycol monoethyl ether as a solvent |
| 02/20/2003 | US20030036562 Water-soluble dendrimeric fullerene as anti-HIV therapeutic |
| 02/20/2003 | US20030036561 Topical composition includes alpha -difluoromethylornithine and a dermatologically acceptable vehicle including urea. |
| 02/20/2003 | US20030036560 Methods and compositions for treating and preventing mucositis |
| 02/20/2003 | US20030036558 Useful in the treatment of chronic complications arising from diabetes, such as neuropathy; may also contain an angiotensin converting enzyme inhibitor. |
| 02/20/2003 | US20030036557 Heterocyclo-substituted imidazoles for the treatment of inflammation |
| 02/20/2003 | US20030036556 Zonisamide use in headache |
| 02/20/2003 | US20030036555 Pramipexole for the treatment of ADHD |
| 02/20/2003 | US20030036554 Oxidizing the corresponding sulfide without sulfone production to product purer omerprazole, lansoprazole, pantoprazole, rabeprazole, etc. |
| 02/20/2003 | US20030036553 Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis |
| 02/20/2003 | US20030036552 Novel compounds |
| 02/20/2003 | US20030036551 Aryl or heteroaryl-substituted tetrahydroisoquinoline derivates possess anti-convulsant activity and are therefore believed to be useful in the treatment and/or prevention of many diseases |
| 02/20/2003 | US20030036549 Methods for treating irritable bowel syndrome |
| 02/20/2003 | US20030036548 Method for treating anhedonia using dopamine agonists |
| 02/20/2003 | US20030036546 Administering an opioidergic composition, such as opiate antagonist, an opiate agonist and a combination thereof. |
| 02/20/2003 | US20030036543 Especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease. |
| 02/20/2003 | US20030036542 Derivatives of pyrimido[6.1-a]isoquinolin-4-one |
| 02/20/2003 | US20030036541 Alkylidene or dialkylidene cephalosporin-type derivatives |
| 02/20/2003 | US20030036539 Use of 2-ME in promotion of apoptosis in the prevention of initial onset and recurrence of existing cancers |
| 02/20/2003 | US20030036536 Substituted benzylthioacetic acids and esters |
| 02/20/2003 | US20030036535 Physiological method of improving vision |
| 02/20/2003 | US20030036534 Naaladase inhibitors for treating retinal disorders and glaucoma |
| 02/20/2003 | US20030036532 Treatment of infections caused by parasites, especially malaria. |
| 02/20/2003 | US20030036531 Use of lysophospholipids to inhibit mammalian phospholipase D |
| 02/20/2003 | US20030036529 Compositions and methods for inhibiting arginase activity |
| 02/20/2003 | US20030036528 Administering a beta-L-(2'-azido)-2',3'-dideoxy-5-fluorocytosine |
| 02/20/2003 | US20030036527 Promoting mucociliary or cough clearance of retained mucus secretions from the lungs, sinuses, upper airways, ears, eyes, genitourinary tract, spermatozoa, ovaries, fallopian tubes, neutrophils, and macrophages |
| 02/20/2003 | US20030036526 Activating a signaling cascade comprising, introducing leptin and/or a cytokine to a receptor complex comprising gp 130, to genes in neuro- endocrine cells or cells of neuro-endocrine origin. |
| 02/20/2003 | US20030036525 Hyaluronic acid and/or a salt thereof associated with/bound with an effective amount of anti-sense to the gene implicated in the disease or condition |
| 02/20/2003 | US20030036524 Transfecting with a polynucleotide that comprises a prodrug metabolising gene, and a promoter capable of selectively promoting the transcription of the prodrug metabolising gene in said endothelial cell; and delivering said prodrug |
| 02/20/2003 | US20030036517 Identifying accessible regions in a target RNA molecule using trans-splicing nucleic acid molecules |
| 02/20/2003 | US20030036515 Method of treating hematologic tumors and cancers |
| 02/20/2003 | US20030036513 Reducing the effective dose of an anti-cancer agent by administering a redox clamping agent, especially Mesna, in conjunction with an anti-cancer agent. |
| 02/20/2003 | US20030036504 Modululation of both fasting and postprandial lipid levels. |
| 02/20/2003 | US20030036502 Methods for enhancing wound healing |
| 02/20/2003 | US20030036501 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus |
| 02/20/2003 | US20030036500 Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
| 02/20/2003 | US20030036204 Surface plasmon enhanced illumination system |